July 21, 2023 07:00 AM EDTUpdated 11:45 AM
Peer Review

Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid com­mer­cial prep

ENDPOINTS

A chunky chain neck­lace, match­ing ear­rings, and a flo­ral shirt with a dozen col­ors — that’s Ig­or Splaws­ki.

The for­mer chief sci­en­tist at Cure­Vac has tak­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times